BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gavazzoni M, Lombardi CM, Vizzardi E, Gorga E, Sciatti E, Rossi L, Belotti A, Rossi G, Metra M, Raddino R. Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: Early in vivo cardiovascular effects. European Journal of Pharmacology 2018;838:85-90. [DOI: 10.1016/j.ejphar.2018.09.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Terpos E, Stamatelopoulos K, Makris N, Georgiopoulos G, Ntanasis-Stathopoulos I, Gavriatopoulou M, Laina A, Eleutherakis-Papaiakovou E, Fotiou D, Kanellias N, Malandrakis P, Delialis D, Andreadou I, Kastritis E, Dimopoulos MA. Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study. Cancers (Basel) 2021;13:5057. [PMID: 34680206 DOI: 10.3390/cancers13205057] [Reference Citation Analysis]
2 Mingrone G, Astarita A, Airale L, Maffei I, Cesareo M, Crea T, Bruno G, Leone D, Avenatti E, Catarinella C, Salvini M, Cetani G, Gay F, Bringhen S, Veglio F, Vallelonga F, Milan A. Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients. Front Cardiovasc Med 2021;8:645678. [PMID: 33969010 DOI: 10.3389/fcvm.2021.645678] [Reference Citation Analysis]
3 Hahn VS, Zhang KW, Sun L, Narayan V, Lenihan DJ, Ky B. Heart Failure With Targeted Cancer Therapies: Mechanisms and Cardioprotection. Circ Res 2021;128:1576-93. [PMID: 33983833 DOI: 10.1161/CIRCRESAHA.121.318223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
4 Cornell RF, Ky B, Weiss BM, Dahm CN, Gupta DK, Du L, Carver JR, Cohen AD, Engelhardt BG, Garfall AL, Goodman SA, Harrell SL, Kassim AA, Jadhav T, Jagasia M, Moslehi J, O'Quinn R, Savona MR, Slosky D, Smith A, Stadtmauer EA, Vogl DT, Waxman A, Lenihan D. Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma. J Clin Oncol 2019;37:1946-55. [PMID: 31188726 DOI: 10.1200/JCO.19.00231] [Cited by in Crossref: 57] [Cited by in F6Publishing: 30] [Article Influence: 19.0] [Reference Citation Analysis]
5 Biersmith MA, Tong MS, Guha A, Simonetti OP, Addison D. Multimodality Cardiac Imaging in the Era of Emerging Cancer Therapies. J Am Heart Assoc 2020;9:e013755. [PMID: 31960741 DOI: 10.1161/JAHA.119.013755] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 6.5] [Reference Citation Analysis]
6 Camilli M, La Vecchia G, Lillo R, Iannaccone G, Lamendola P, Montone RA, Hohaus S, Aspromonte N, Massetti M, Lanza GA, Crea F, Graziani F, Lombardo A. Cardiovascular involvement in patients affected by multiple myeloma: a comprehensive review of recent advances. Expert Rev Hematol 2021;:1-14. [PMID: 34739762 DOI: 10.1080/17474086.2021.2003704] [Reference Citation Analysis]